Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04037865 · ClinicalTrials.gov registry record · Phase 1
A Renal Impairment Study for PF-06651600
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04037865: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT04037865 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04037865, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 1 non-randomized, open-label, parallel cohort study of PF-06651600 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with mild and moderate renal impairment (Part 2).
Primary Outcome
The plasma PF-06651600 Cmax was observed directly from data.
Interventions
- DRUG PF-06651600
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 1 |
Why NCT04037865 stopped before completion
NCT04037865 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which PF-06651600 is the first listed.
NCT04037865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04037865 about?
NCT04037865 is a clinical study titled "A Renal Impairment Study for PF-06651600". This is a Phase 1 non-randomized, open-label, parallel cohort study of PF-06651600 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with mild and moderate renal impairment (Part 2).
What is the current status of trial NCT04037865?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-08-19. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT04037865?
The interventions under investigation include: PF-06651600 (DRUG).
Who is sponsoring clinical trial NCT04037865?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04037865's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI